Trial Profile
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant setting
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2019
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 24 May 2018 Status changed from recruiting to completed.
- 26 May 2017 New trial record